MS4A1 and lymphoma: Obinutuzumab, a second-generation anti-CD20 monoclonal antibody engineered with glycoengineered Fc modifications to enhance antibody-dependent cellular cytotoxicity (ADCC), has demonstrated superior efficacy over rituximab in indolent lymphomas (9).